"Voyager Therapeutics and Novartis Forge $1.3B Gene Therapy Mega-Deal"

Voyager Therapeutics has announced a strategic collaboration and capsid license agreement with Novartis to develop gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will receive $100 million upfront and is eligible for up to $1.2 billion in milestone payments, plus royalties. The partnership leverages Voyager's TRACER capsid discovery platform, which is designed to enhance delivery of gene therapies to the central nervous system. Novartis will handle development and commercialization, while Voyager focuses on preclinical advancement.